

Title (en)
USE OF EXTRACTS OF ECHINACEA PALLIDA AND ECHINACEA ANGUSTIFOLIA, DANDELION (TARAXACUM) AND PLANTAIN (PLANTAGO)

Title (de)
VERWENDUNG VON ECHINACEA PALLIDA UND ECHINACEA ANGUSTIFOLIA-EXTRAKTEN; LÖWENZAHN-(TARAXACUM)-EXTRAKTEN; SPITZWEGERICH-(PLANTAGO)-EXTRAKTEN

Title (fr)
UTILISATION D'EXTRAITS D'ECHINACEA PALLIDA ET D'ECHINACEA ANGUSTIFOLIA; EXTRAITS DE DENTS DE LION (TARAXACUM); EXTRAITS DE PLANTAIN (PLANTAGO)

Publication
EP 1067947 A1 20010117 (DE)

Application
EP 99917908 A 19990326

Priority
• DE 19814725 A 19980402
• EP 9902152 W 19990326

Abstract (en)
[origin: DE19814725A1] The invention relates particularly to the use of extracts of Echinacea pallida (EP) and Echinacea angustifolia (EA), dandelion (Taraxacum, TA) and plantain (Plantago, PL), especially dry extracts from the fresh or dried plants, to produce medicaments for treating or preventing (protecting against) damage caused to organs and tissue by radiation (radioprevention, radioprotection), infection (infection prophylaxis) and chemical action (chemoprevention, chemoprotection), especially damage to the O-MALT system of the small bowel (inflammatory diseases, enteritis regionalis Crohn), the lungs (inflammation, disease), the bronchial tubes and the rhinopharynx (rhino-pharyngo-bronchitis, rhinitis, pharyngitis, sinusitis), the bone marrow (aplasia of the bone marrow), the thymus (dysfunction, aplasia or hypoplasia resulting from damage caused by medicaments or radiation) and the liver (atrophy, necrosis), for treating/preventing hepatitis A, B and C, for damage to the pancreas, insufficiency of the exocrine, secretory functions of proteases, esterases, carbohydrases and nucleases and impairment of the carbohydrate metabolism (Langerhans' islands), damage to the kidneys (insufficiency), and generally immunosuppressed conditions, for cellular immunostimulation, for treating leucocytopenia, granulocytopenia, lymphocytopenia, thrombocytopenia, erythrocytopenia (infect anaemia, tumour anaemia i.a.), immunoglobulin deficiency conditions, and for conditions resulting from AIDS, tumours and diseases with a suppressed immune system.

IPC 1-7
A61K 35/78

IPC 8 full level
A61K 36/00 (2006.01); **A61K 36/185** (2006.01); **A61K 36/28** (2006.01); **A61K 36/288** (2006.01); **A61K 36/68** (2006.01); **A61P 31/18** (2006.01); **A61P 37/04** (2006.01)

CPC (source: EP)
A61K 36/185 (2013.01); **A61K 36/28** (2013.01); **A61K 36/288** (2013.01); **A61K 36/68** (2013.01); **A61P 31/18** (2017.12); **A61P 37/04** (2017.12); **Y02A 50/30** (2017.12)

Citation (search report)
See references of WO 9951250A1

Designated contracting state (EPC)
AT BE CH DE DK ES FI FR GB IT LI LU NL SE

DOCDB simple family (publication)
DE 19814725 A1 19991007; AU 3602199 A 19991025; EP 1067947 A1 20010117; WO 9951250 A1 19991014

DOCDB simple family (application)
DE 19814725 A 19980402; AU 3602199 A 19990326; EP 9902152 W 19990326; EP 99917908 A 19990326